1,024 material Form 8-K filings that 799 companies we cover made with the SEC in August 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On August 1, 2025, United Therapeutics entered two accelerated share repurchase agreements with Citibank, N.A., totaling $1 billion under the $1 billion program its board approved on July 30, 2025. The company makes the full $1 billion upfront payment to Citi on August 4, 2025, and receives initial share deliveries that day, with the final number of shares repurchased to be set by future average prices. For shareholders, the buyback is a large use of company cash, and the filing does not yet state the total number of shares that will be repurchased.
Two agreements of $500 million each: an uncollared ASR and a collared ASR with Citi.
Aggregate upfront payment of $1 billion to Citi due August 4, 2025.
Initial deliveries on August 4, 2025 of about 1,274,296 shares (uncollared) and about 849,531 shares (collared).
Final settlement expected in the fourth quarter of 2025 (uncollared) and the first quarter of 2026 (collared).
On August 1, 2025, Amneal Pharmaceuticals LLC borrowed $2.1 billion of new seven-year term loans and completed a $600 million offering of 6.875% senior secured notes due 2032. The company used the proceeds to refinance its existing term loans, which had about $2.26 billion outstanding, and to repay its ABL facility in full. The filing describes a refinancing that replaces existing debt and extends maturities rather than adding a stated new use of cash.
New $2.1 billion term loan matures August 1, 2032, with interest at term SOFR plus a 3.50% margin
$600 million of 6.875% senior secured notes due August 1, 2032, issued at 100% of principal amount
Existing term loan of about $2.26 billion refinanced in full; ABL facility repaid and its maturity extended to August 1, 2030 with $600 million of commitments
On August 1, 2025, EOG Resources completed its previously announced acquisition of Encino Acquisition Partners, LLC, buying all outstanding equity interests from the sellers for $5.6 billion in cash, including repayment of debt. The price is subject to customary working capital and other adjustments, and the full purchase agreement will be filed with EOG's 10-Q for the quarter ended June 30, 2025.
Purchase price: $5.6 billion in cash, inclusive of debt repayment, subject to customary adjustments
Closing date: August 1, 2025; purchase agreement dated May 30, 2025
Structure: part through acquisition of Blocker Corp, part through direct purchase of equity interests in Encino
Full agreement to be filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2025
Essential Utilities reported second-quarter 2025 net income of $107.8 million, or $0.38 per share, up from $75.4 million, or $0.28 per share, a year earlier, on revenue of $514.9 million, up 18.5%. The company expects 2025 GAAP earnings per share above its $2.07-$2.11 guidance range due to non-recurring benefits, and it raised its quarterly dividend by 5.25%.
Q2 2025 net income $107.8 million, or $0.38 per share, versus $75.4 million, or $0.28 per share, in Q2 2024
Q2 2025 revenues $514.9 million, up 18.5% from $434.4 million; operations and maintenance expense rose to $148.5 million from $142.5 million
2025 GAAP EPS expected above the $2.07-$2.11 guidance range due to non-recurring benefits; 2025 infrastructure investment expected at $1.4 to $1.5 billion
Quarterly dividend increased to $0.3426 per share, payable September 2, 2025, to holders of record on August 12, 2025
Insperity reported second-quarter 2025 revenue up 3% to $1.7 billion, but swung to a net loss of $5 million, or $(0.14) per diluted share, from net income of $18 million a year earlier. The company said higher-than-expected benefits costs drove the decline and lowered its 2025 guidance.
Q2 2025 revenues rose 3% to $1.7 billion; gross profit fell 14% to $223 million.
Q2 2025 adjusted EBITDA was $32 million and adjusted EPS was $0.26, versus $0.86 in Q2 2024.
Updated full-year 2025 guidance: adjusted EPS of $1.81 to $2.51 and adjusted EBITDA of $170 million to $205 million; Q3 2025 adjusted EPS of $0.06 to $0.49.
On July 31, 2025, Insperity also announced an updated HR solutions portfolio, including Insperity HRScale with Workday, which the company said will be available to early adopter customers in 2026.
Grainger reported second-quarter 2025 sales of $4.6 billion, up 5.6%, and diluted EPS of $9.97, up 4.8% on a reported basis, while its operating margin fell 20 basis points to 14.9%. The company lowered its full-year 2025 adjusted diluted EPS guidance to $38.50-$40.25 from $39.00-$41.50, citing tariff-related headwinds, which matters to shareholders because it reduces the earnings outlook even as the quarter's top-line and per-share results grew.
Q2 2025 net sales were $4.6 billion, up 5.6% (5.1% on a daily, constant currency basis).
Diluted EPS was $9.97, up 4.8% reported and 2.2% adjusted; the company said the increase was driven primarily by fewer shares outstanding.
Full-year 2025 adjusted diluted EPS guidance was lowered to $38.50-$40.25 from $39.00-$41.50 as of May 1, 2025.
Operating cash flow was $377 million, and the company returned $336 million to shareholders through dividends and share repurchases.
Colgate-Palmolive reported second-quarter 2025 net sales of $5,110 million, up 1.0%, and GAAP diluted EPS of $0.91, up 2%, while narrowing its full-year organic sales growth outlook to the low end of 2% to 4%. The company also approved a three-year productivity program with projected pre-tax charges of $200 million to $300 million, which will weigh on reported results through December 31, 2028.
Q2 2025 net sales were $5,110 million, up 1.0%; organic sales rose 1.8%, including a 0.6% negative impact from lower private label pet sales.
GAAP diluted EPS was $0.91, up from $0.89; GAAP gross profit margin fell 50 basis points to 60.1%.
Full-year 2025 organic sales growth is now expected at the low end of 2% to 4%; GAAP EPS is still expected to rise low single digits.
The productivity program carries projected cumulative pre-tax charges of $200 million to $300 million over three years, with substantially all incurred by December 31, 2028, recorded in the Corporate segment.
Oshkosh reported second-quarter 2025 net sales of $2.73 billion, down 4.0% from a year earlier, and GAAP diluted EPS of $3.16 versus $2.56, with adjusted EPS of $3.41 versus $3.34. The company raised its 2025 adjusted EPS expectation to approximately $11.00 and its GAAP EPS expectation to approximately $10.25, while keeping its net sales outlook at about $10.6 billion. The filing also announced a $0.51 quarterly dividend.
Q2 net sales decreased $114.8 million, or 4.0%, to $2.73 billion, mainly on lower Access and Transport volume
Q2 GAAP diluted EPS was $3.16 versus $2.56; adjusted diluted EPS was $3.41 versus $3.34
2025 adjusted EPS expectation raised to approximately $11.00; GAAP EPS expectation approximately $10.25; net sales expectation about $10.6 billion, unchanged
Quarterly dividend of $0.51 per share, payable September 2, 2025 to holders of record August 19, 2025
Cboe Global Markets reported second-quarter 2025 results on August 1, 2025, with net revenue of $587.3 million, up 14% from a year earlier, and adjusted diluted EPS of $2.46, up 14%. The company raised its 2025 organic total net revenue growth target to high single digits and lowered its adjusted operating expense guidance, which points to higher expected revenue and slightly lower expected costs for the year.
Net revenue of $587.3 million rose 14% from $513.8 million in Q2 2024, with Derivatives net revenue up 17%.
Diluted EPS of $2.23 rose 68%, primarily due to a non-recurring 2024 impairment; adjusted diluted EPS of $2.46 rose 14%.
2025 organic total net revenue growth target raised to high single digits from mid to high single digits; adjusted operating expense guidance lowered to $832 million to $847 million from $837 million to $852 million.
Cboe plans to suspend Japanese equities operations on August 29, 2025, with normalized annual adjusted operating expense savings of $10 million to $12 million.
Fluor reported second-quarter 2025 revenue of $4.0 billion, down 6% from a year earlier, and adjusted EPS of $0.43, down 49%. The company lowered its 2025 adjusted EBITDA guidance to $475 million to $525 million from $575 million to $675 million, citing client hesitation around economic uncertainty, along with cost growth on three infrastructure projects. Reported GAAP net earnings of $2.5 billion were driven by a $3.2 billion pre-tax NuScale mark-to-market gain, so the adjusted figures and lower outlook are the more direct read on operating performance for shareholders.
Q2 revenue of $4.0 billion, down 6% year over year; adjusted EBITDA of $96 million, down 42%.
Adjusted EPS of $0.43 versus $0.85 a year earlier; GAAP EPS of $14.81 includes $3.2 billion in pre-tax NuScale mark-to-market gains.
2025 adjusted EBITDA guidance revised to $475 million to $525 million from $575 million to $675 million; adjusted EPS guidance to $1.95 to $2.15 from $2.25 to $2.75.
Q2 operating cash flow was negative $21 million; backlog was $28.2 billion, down 13% from $32.3 billion a year ago.
Moderna reported second-quarter 2025 total revenue of $142 million, down 41% from $241 million a year earlier, and a net loss of $825 million, or $2.13 per share, versus a $3.33 loss per share a year earlier. The company lowered the high end of its 2025 revenue range by $300 million to $1.5 to $2.2 billion, mainly because some U.K. contracted deliveries shifted into the first quarter of 2026, while it expects operating expenses to improve by about $400 million.
Q2 2025 total revenue was $142 million, down 41% from $241 million; Q2 net loss was $825 million, versus $1.3 billion a year earlier
2025 revenue range is now $1.5 to $2.2 billion, a $300 million reduction at the high end
2025 GAAP operating expenses are now expected at $5.9 to $6.1 billion, an improvement of about $400 million
Year-end 2025 cash balance expected at about $6 billion; cash and investments were $7.5 billion as of June 30, 2025
Xenia Hotels & Resorts reported second-quarter 2025 net income attributable to common stockholders of $55.2 million, or $0.56 per share, compared with $15.3 million, or $0.15 per share, a year earlier. The company raised its full-year 2025 guidance for Adjusted EBITDAre and Adjusted FFO, citing second-quarter outperformance and an unchanged outlook for the second half.
Q2 2025 Adjusted EBITDAre was $79.5 million, up 16.3% from Q2 2024; Adjusted FFO per diluted share was $0.57, up 9.6%.
Same-Property RevPAR rose 4.0% to $195.51 in Q2, and Same-Property Hotel EBITDA rose 22.2% to $84.0 million.
Full-year 2025 Adjusted EBITDAre guidance is $249 million to $263 million, and Adjusted FFO per diluted share guidance is $1.66 to $1.80.
In Q2 the company repurchased 2,948,912 shares for approximately $35.7 million and had $146.4 million left under its repurchase authorization.
nVent reported second-quarter 2025 net sales of $963 million, up 30%, and GAAP diluted EPS from continuing operations of $0.65, up 18%. The company raised its full-year 2025 reported sales growth outlook to 24% to 26% and raised its adjusted EPS guidance to $3.22 to $3.30, while its GAAP EPS guidance range narrowed to $2.48 to $2.56, with a lower top end than before.
Q2 2025 net sales of $963 million, up 30%; organic sales up 9%
Q2 adjusted EPS from continuing operations of $0.86, up 28%; GAAP EPS of $0.65, up 18%
Full-year 2025 adjusted EPS guidance raised to $3.22 to $3.30 from $3.03 to $3.13
Q2 free cash flow of $74 million, compared with $101 million in Q2 2024
Kimberly-Clark reported second quarter 2025 results, with net sales of $4.2 billion down 1.6% from a year earlier and adjusted diluted EPS of $1.92, down 2.0%. The company also raised its 2025 outlook, although the filing's outlook figures are framed as growth ranges and reflect the divestiture of its PPE business and exit of its US private label diaper business.
Q2 net sales were $4.2 billion, down 1.6%, while organic sales rose 3.9% on 5.0% volume growth.
Diluted EPS was $1.53 versus $1.61 a year earlier; adjusted EPS was $1.92, down 2.0%.
The 2025 outlook was raised; adjusted free cash flow is expected to be about $2 billion in 2025.
Newell Brands reported second quarter 2025 net sales of $1.9 billion, down 4.8% from a year earlier, and normalized diluted EPS of $0.24 versus $0.35. Gross margin rose to 35.4%, but the company also updated its full year 2025 outlook to include higher tariff costs, with normalized EPS now expected at $0.66 to $0.70 and operating cash flow at $400 million to $450 million. For shareholders, lower sales and profit alongside higher tariff costs weigh on the outlook.
Net sales were $1.9 billion, down 4.8%; core sales declined 4.4%
Normalized diluted EPS was $0.24 versus $0.35; GAAP diluted EPS was $0.11, unchanged
Full year 2025 normalized EPS outlook is $0.66 to $0.70; operating cash flow outlook is $400 million to $450 million
Year-to-date operating cash outflow was $271 million; company estimates incremental cash tariff cost of about $155 million versus 2024
Interface reported second-quarter 2025 net sales of $376 million, up 8% from a year earlier, and GAAP diluted earnings per share of $0.55, up 45%. The company raised its full-year 2025 net sales outlook to $1.370 billion to $1.390 billion from $1.340 billion to $1.365 billion, which gives shareholders a higher revenue range for the year.
Q2 net sales $375.5 million, up 8.3% (7.1% currency neutral); Americas currency-neutral sales up 11%
GAAP diluted EPS $0.55 vs $0.38 a year earlier; adjusted diluted EPS $0.60 vs $0.40
Full-year 2025 net sales outlook raised to $1.370 billion to $1.390 billion; Q3 net sales outlook $350 million to $360 million
Q2 adjusted gross profit margin 39.8%, up 402 basis points year over year
Ingredion reported second-quarter 2025 diluted EPS of $2.99, up from $2.22 a year earlier, and adjusted EPS of $2.87, flat year over year. Net sales fell 2% to $1.83 billion, while the company raised its full-year 2025 reported EPS guidance to $11.25 to $11.75 and adjusted EPS guidance to $11.10 to $11.60.
Q2 2025 net sales were $1.83 billion, down 2% from $1.88 billion a year earlier.
Q2 operating income rose 13% to $271 million; adjusted operating income was $273 million, up 1%.
Full-year 2025 reported EPS guidance is $11.25 to $11.75, and adjusted EPS guidance is $11.10 to $11.60.
The company cited a mechanical fire that briefly shut down its Chicago plant as a negative factor in the F&II U.S./Canada segment.
BrightSpring Health Services reported second-quarter 2025 results on August 1, 2025, with net revenue up 29.1% and Adjusted EBITDA up 28.8%, both excluding the Community Living business. The company raised its full-year 2025 revenue and Adjusted EBITDA guidance, while net income from continuing operations was flat at $8.5 million. The planned sale of Community Living to Sevita is expected to close in the fourth quarter of 2025.
Q2 2025 net revenue was $3,148 million, up 29.1% from $2,438 million a year earlier.
Adjusted EBITDA was $143 million, up 28.8% from $111 million; net income from continuing operations was $8.5 million, flat year over year.
2025 revenue guidance was raised to $12,200 million-$12,600 million, and Adjusted EBITDA guidance to $590 million-$605 million.
The Community Living divestiture to Sevita, announced January 20, 2025, is expected to close in Q4 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.